<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260426069165N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-05-05</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the Effects of Using a Hemostatic Focus Scalpel on Postoperative Complications of Thyroidectomy Compared to the Conventional Method: A Clinical Trial</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effects of Using a Hemostatic Focus Scalpel on Postoperative Complications of Thyroidectomy Compared to the Conventional Method: A Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/89808</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible patients, after signing the written informed consent form, will be allocated to one of the two study groups (HS group or CT group) using a block randomization method (randomized block design). Allocation concealment will be ensured through the use of sealed, opaque, numbered envelopes. The envelope corresponding to each patient will be opened immediately before the start of surgery, after final confirmation of the patient’s eligibility, by a nurse who is not involved in the surgical procedure or outcome assessment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hemostasis status in open thyroidectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, hemostasis of the thyroid vessels (superior, middle, and inferior thyroid arteries and veins) and division of the thyroid tissue will be performed using the **Focus Harmonic Scalpel** (Ethicon Endo‑Surgery). The use of **sutures** or **electrocautery** will be minimized and applied only when necessary — for example, in cases of bleeding from vessels exceeding the device’s sealing capacity or diffuse oozing. Intervention 2: Control group: In this group, the conventional hemostasis technique will be used. Major vessels will be clamped with surgical clamps and then ligated with absorbable suture material (such as 2‑0 or 3‑0 Vicryl) using the clamp‑and‑tie method. For control of bleeding from smaller vessels and the thyroid bed, monopolar or bipolar electrocautery may also be utilized.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is A definitive decision regarding the sharing of participants’ de-identified individual data has not yet been made. This is because a thorough assessment of potential data re-identification risks, legal frameworks, and institutional requirements related to data sharing has not been completed. Furthermore, prior to study completion, a comprehensive evaluation of data quality, standardization, and the feasibility of complete anonymization is necessary. A final decision on data sharing will be made after the study concludes and these aspects have been comprehensively evaluated</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abouzar Pourrashidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Afzalipour hospital, Imam Khomeini Local Lane</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 913 393 1624</telephone>
        <email>abz_pur@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abouzar Pourrashidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Afzalipour hospital, Imam Khomeini Local Lane</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 913 393 1624</telephone>
        <email>abz_pur@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Individuals aged 18 years or older
Patients scheduled for primary open thyroidectomy (first-time thyroid surgery)
Ability to understand the study and to sign a written informed consent form</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, hemostasis of the thyroid vessels (superior, middle, and inferior thyroid arteries and veins) and division of the thyroid tissue will be performed using the **Focus Harmonic Scalpel** (Ethicon Endo‑Surgery). The use of **sutures** or **electrocautery** will be minimized and applied only when necessary — for example, in cases of bleeding from vessels exceeding the device’s sealing capacity or diffuse oozing.</i_keyword>
      <i_keyword>Control group: In this group, the conventional hemostasis technique will be used. Major vessels will be clamped with surgical clamps and then ligated with absorbable suture material (such as 2‑0 or 3‑0 Vicryl) using the clamp‑and‑tie method. For control of bleeding from smaller vessels and the thyroid bed, monopolar or bipolar electrocautery may also be utilized.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Duration of surgery. Timepoint: Time from skin incision to skin closure. Method of measurement: Surgical procedure description.</prim_outcome>
      <prim_outcome>Intraoperative blood loss. Timepoint: end of the procedure. Method of measurement: Surgical procedure description.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hypocalcemia. Timepoint: Postoperatively and at 6 months postoperatively. Method of measurement: Lab tests.</sec_outcome>
      <sec_outcome>RLN paralysis. Timepoint: Postoperatively and at 6 months postoperatively. Method of measurement: Patient clinical record.</sec_outcome>
      <sec_outcome>Postoperative hematoma. Timepoint: end of the procedure. Method of measurement: Patient clinical record.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-07</approval_date>
        <contact_name>The Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Afzalipour hospital, Imam Khomeini Local Lane Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
